Amylyx Pharmaceuticals (AMLX) Research & Development (2021 - 2025)
Historic Research & Development for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $19.9 million.
- Amylyx Pharmaceuticals' Research & Development fell 650.75% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.1 million, marking a year-over-year decrease of 2697.97%. This contributed to the annual value of $104.1 million for FY2024, which is 1880.3% down from last year.
- According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Research & Development is $19.9 million, which was down 650.75% from $27.2 million recorded in Q2 2025.
- Over the past 5 years, Amylyx Pharmaceuticals' Research & Development peaked at $44.9 million during Q4 2023, and registered a low of $6.9 million during Q1 2021.
- Its 5-year average for Research & Development is $23.1 million, with a median of $22.9 million in 2024.
- As far as peak fluctuations go, Amylyx Pharmaceuticals' Research & Development skyrocketed by 21270.4% in 2022, and later plummeted by 4903.15% in 2024.
- Over the past 5 years, Amylyx Pharmaceuticals' Research & Development (Quarter) stood at $13.4 million in 2021, then surged by 70.32% to $22.8 million in 2022, then surged by 96.88% to $44.9 million in 2023, then crashed by 49.03% to $22.9 million in 2024, then dropped by 13.27% to $19.9 million in 2025.
- Its last three reported values are $19.9 million in Q3 2025, $27.2 million for Q2 2025, and $22.1 million during Q1 2025.